Tomohide Sugiyama
YOU?
Author Swipe
View article: Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study Open
The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. …
View article: Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations Open
Background and Objectives: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non-small-cell lung cancer (NSCLC) harboring drug-sensitive EGFR…
View article: Prognostic value of morphological characteristics assessed by <scp>CT</scp> scan in patients with <scp>non‐small</scp> cell lung cancer treated with nivolumab
Prognostic value of morphological characteristics assessed by <span>CT</span> scan in patients with <span>non‐small</span> cell lung cancer treated with nivolumab Open
Background Nivolumab is known to demonstrate superior overall survival compared with docetaxel in pretreated non‐small cell lung cancer (NSCLC) patients. Programmed death‐ligand 1 (PD‐L1) expression is reported to predict the outcome of tr…
View article: Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer Open
View article: Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis
Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis Open
Background Topotecan is one of the most active chemotherapeutic drugs for small cell lung cancer (SCLC). However, its efficacy in elderly patients with SCLC has not been validated. This study evaluated the feasibility and efficacy of topot…
View article: Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study
Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study Open
Background The prognostic factors and the efficacy of first-line chemotherapy remain unclear in patients with advanced thymic carcinoma. Materials and Methods We conducted a multi-institutional retrospective study named NEJ023 for patients…
View article: A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients Open
View article: The Antiemetic Efficacy of Aprepitant in Patients with Advanced Non-small-cell Lung Cancer Who Are Treated with Pemetrexed and Carboplatin
The Antiemetic Efficacy of Aprepitant in Patients with Advanced Non-small-cell Lung Cancer Who Are Treated with Pemetrexed and Carboplatin Open
目的．カルボプラチン/ペメトレキセド併用療法におけるアプレピタントの有用性を明らかにする．方法．カルボプラチン（AUC 6），ペメトレキセド（500 mg/m2）を1日目に投与し，3週毎に投与した．1コース目ではアプレピタントを投与せず，悪心がGrade 2以上であった14症例に対し，2コース目よりアプレピタントを追加併用し，制吐作用について検討した．結果．男性/女性：11/3例，年齢中央値62歳．PSは0/1：4/10例，全例腺癌であった．1コース目の悪心はGrade 2…